The synthesis and biological evaluation of novel 1-aryl-3-[2-, 3-or 4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 3, 4 and 5 as VEGFR-2 tyrosine kinase inhibitors, are reported. pyridin-7-ylthio)phenyl]ureas 4a-4h, with the arylurea in the meta position to the thioether, showed the lowest IC 50 values in enzymatic assays (10-206 nM), the most potent compounds 4d-4h (IC 50 10-28 nM) bearing hydrophobic groups (Me, F, CF 3 and Cl) in the terminal phenyl ring. A convincing rationalization was achieved for the highest potent compounds 4 as type II VEGFR-2 inhibitors, based on the simultaneous presence of: (1) the thioether linker and (2) the arylurea moiety in the meta position. For compounds 4, significant inhibition of Human Umbilical Vein Endothelial Cells (HUVECs) proliferation (BrdU assay), migration (wound-healing assay) and tube formation were observed at low concentrations. These compounds have also shown to increase apoptosis using the TUNEL assay. Immunostaining for total and phosphorylated (active) VEGFR-2 was performed by Western blotting. The phosphorylation of the receptor was significantly inhibited at 1.0 and 2.5 M for the most promising compounds. Altogether, these findings point to an antiangiogenic effect in HUVECs.
Introduction
The Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) is a class V Receptor Tyrosine Kinase (RTK), expressed primarily in endothelial cells, and is activated by the specific binding of Vascular Endothelial Growth Factor (VEGF), secreted by endothelial cells and various tumor cells, to the VEGFR-2 extracellular regulatory domain. Once activated, VEGFR-2 undergoes autophosphorylation, triggering signalling pathways leading to endothelial cell proliferation and subsequent tumor angiogenesis that promotes tumor growth and metastasis. 1 Several small-molecule VEGFR-2 inhibitors have emerged as promising antiangiogenic agents for treatment against a wide variety of cancers and act by competing with adenosine triphosphate (ATP) for the ATP-binding site of the VEGFR-2 intracellular kinase domain, thereby preventing the intracellular signalling. This leads to angiogenesis, 2 the sprouting of new capillaries from pre-existing blood vessels, which is a multistep process involving endothelial cell differentiation, proliferation, migration, permeability and tube formation. These assays are used to reproduce the angiogenesis process in vitro. 3 Most known kinase inhibitors are classified as type I kinase inhibitors, which bind in and around the region occupied by the adenine ring of ATP. 4 Sunitinib is a classical example of a type I inhibitor and has been approved for the treatment of renal cell carcinomas and gastrointestinal stromal tumors. 5 On the other hand, type II kinase inhibitors induce the inactive DFG-out conformation of the activation loop, enabling them to occupy the adenine binding site and an adjacent hydrophobic pocket created by this rearrangement. As the residues forming the hydrophobic pocket are less conserved than residues in the adenine pocket, type II inhibitors usually provide a better kinase selectivity when compared to type I inhibitors. 4, 6 For VEGFR-2, several type II inhibitors have been reported. These inhibitors occupy the adenine pocket with a suitable ring or ring system that is able to promote 1 to 3 H-bonds with the kinase hinge region (Glu917-Cys919); while also occupying the hydrophobic pocket that is available in the DFG-out conformation (Asp1046-Phe1047-Gly1048 for VEGFR-2), with a suitable ring or ring system. A pair of hydrogen bond donating and accepting groups, (usually an urea or a corresponding bioisosteric core) is also present to establish H-bonds with Asp1046 and Glu885. The ring systems occupying both the adenine and the hydrophobic pocket are usually linked via a central ring positioned in an intermediate linker region (Figure 1 and 2).
A number of type II VEGFR-2 inhibitors, relevant for the discussion of the results are presented in figure 1. They present a typical pharmacophore model for these inhibitors where a central aryl ring, occupying the linker region, is bound to the ring occupying the adenine pocket via an ether linker (O-linker), while the ring in the hydrophobic pocket is bound to the central ring via an urea group in para position to the O-linker. In the course of molecular modelling studies performed in our group and following a previous study presenting thieno [3,2-d] pyrimidines as VEGFR-2 inhibitors, several observations suggested that alternatives to the O-linker using different configuration patterns, could be explored in an attempt to synthesize original VEGFR-2 inhibitors. 10 Specifically the use of a thioether linker (S-linker) instead of an ether linker (O-linker) could provide interesting compounds with potent VEGFR-2 inhibition capability and with an alternative profile to the existent type II VEGFR-2 inhibitor scaffolds. Sorafenib was used for comparison with compounds that present similar substituents in the terminal aryl ring located in the hydrophobic pocket. examined by BrdU, TUNEL, wound healing and matrigel assays, and by Western blot, respectively.
Results and Discussion

Synthesis
The 7-chlorothieno [3,2- 
ii) i) K 2 CO 3 (4 equiv.), DMF, 140ºC, 2h ii) arylisocyanates (1 equiv.), CH 2 Cl 2 : THF (1:1), rt, 12h 
Scheme 1. Synthesis of the 2-, 3-or 4-(thieno [3,2-b] pyridin-7-ylthio)anilines 2a-c and of the 1-aryl-
Enzymatic Inhibition and Structure Activity-Relationship
Compounds 3a-c, 4a-c and 5a-c were first synthetized and subsequently evaluated for their ability to interact with the VEGFR-2 kinase domain (Table 1) , using an enzymatic FRET-based assay. 12 The three series differ in the position of the arylurea scaffold; with compounds 3, 4 and 5 bearing it in the ortho, meta and para-position relative to the thioether linker, respectively. Compounds 4a-c displayed the highest enzyme inhibition potency with IC 50 values of 94, 107 and 206 nM, respectively; whereas compounds 5a , 5b displayed either moderate, 1160 and 1390 nM, respectively, or 5c weak VEGFR-2 inhibition activity, 8360 nM; compounds 3a-c were inactive.
These findings are surprising as compounds 5 present similarities with known VEGFR-2 inhibitors with the arylurea moiety in the para position, [8] [9] [10] [13] [14] [15] including the drug Sorafenib ( Figure 1 ). 7 Instead, compounds 4a-4c with the arylurea group in the meta position, were an order of magnitude more potent. The arylurea in the meta position is usually not considered as a promising feature and the studies using different scaffolds as potential VEGFR-2 inhibitors always explore the arylurea in the para position 7-10, 13-15 although presenting an O-linker instead of a S-linker.
In fact, considering the number of scaffolds with VEGFR-2 inhibitory activity already published, it is surprising that a S-linker in meta position relative to the urea moiety was not explored before by others. The explanation is probably inherent to the rational of the drug design process where only one feature is explored at a time. We have found at least two studies performed by Hasegawa et al. 8 and Oguro et al. 9 where the importance of the O/S linker atom and the meta/para position relative to the urea moiety was analyzed in a series of benzimidazole and pyrrolo [3,2- Typically, for type II VEGFR-2 inhibitors, the terminal aryl ring that occupies the hydrophobic pocket is functionalized with hydrophobic substituent groups, the most frequent being methyl groups or halogen atoms in meta or para position, although other substitution pattern is observed ( Figure 1 ). Based on this information compounds 4d-h were synthetized in an attempt to obtain more potent VEGFR-2 inhibitors than compounds 4a-4c. Compounds 4d with a F atom in the para position or 4e with a F in the meta position, 4f with a methyl group, 4g with a CF 3 both in the meta position and 4h with a CF 3 in meta and a Cl in the para position, relative to the urea moiety, were 16 In order to explain the VEGFR-2 inhibitory activity of compounds 4, we set out to investigate in detail the binding mode of compounds 4d and 4f and 5a by performing molecular docking studies.
Molecular Docking Simulations
To better understand the structural rational behind the VEGFR-2 inhibition potency observed for the synthesized compounds, molecular docking simulations were performed using AutoDock4 software.
The VEGFR-2 kinase domain crystal structure with PDB code: 3VHE was selected because it presented a co-crystallized inhibitor (compound B, Figure 1 ) with the closest structure compared to the compounds prepared in this work. For a suitable comparison, compounds 5a and compounds 4d and 4f were docked against the selected structure and then superimposed with the experimental structure of compound B (Figure 2A and 2B). The other compounds of series 5 were also docked and the obtained docking poses were a near perfect superimposition of compound 5a docking pose.
So for clearance of representation on figure 2A only compound 5a was used as it is the simplest, without substitution in the terminal aryl ring.
For the less potent compound 5a a similar binding mode pattern to compound B was observed The higher inhibition potency of compound 4d with an F atom in the para position and 4f with a methyl group in the meta position, relative to the urea moiety, when compared to compound 4a with no substitution, is also widely observed for other known type II inhibitors ( Figure 1 ) and it is due to a better occupation of the hydrophobic pocket. [13] [14] [15] This observation further demonstrates that the predicted docked poses are probably correct. 
Cell Culture Assays
The best compounds in enzymatic assays (4a-h) against VEGFR-2 tyrosine kinase domain were examined in cell culture viability and proliferation assays using HUVECs stimulated by VEGF. Cell viability was first analyzed by MTS assay ( Figure 3 ). The effects of compounds 4a-f at 0.1 to 10 µM on HUVECs viability are shown in Figure 3A . Cell viability was reduced by each compound at a dose-dependent manner, reaching statistical significance at the concentration of 5.0 µM or higher.
The effects of compounds 4g and 4h on HUVECs viability were analyzed. Given the similarity of the hydrophobic chemical pattern substitution of Sorafenib, this drug was used as a positive control for compounds 4g and 4h, these two compounds being used at 1.0 to 10 µM, the concentrations established for Sorafenib in cell culture assays ( Figure 3B ). Compound 4g significantly reduced the cell viability at 10 µM, while compound 4h did it at 2.5, 5.0 and 10 µM. Nevertheless, they only affected more than 50% cell viability (4g = 44%, 4h = 26%), revealing a cytotoxic effect on
HUVECs for the highest concentration tested (10 µM), as Sorafenib (18%). Altogether, these findings reveal that every compound was able to decrease HUVECs viability. Though, compounds 4g and 4h presented significant reductions at lower concentrations. Compounds 4g (R 2 = CF 3 ), 4h (R 1 = Cl; R 2 = CF 3 ) significantly inhibited proliferation of HUVECs at 2.5 and 5.0 µM, without high cytotoxic effect. Sorafenib is known to prevent cell growth in endothelial cells. 7 Interestingly enough, compounds 4g and 4h exhibit, thus, a more noteworthy effect than Sorafenib, which only significantly affected proliferation of these cells at 5.0 M ( Figure   4B ).
These results showed that all the tested compounds considerably inhibit VEGF-stimulated HUVECs proliferation in a dose-dependent manner at low concentrations. 
Effect on Apoptosis
The induction of apoptosis is a therapeutic approach for cancer treatment. Several anticancer drugs, including some VEGFR-2 inhibitors can promote apoptosis. 19 The effect of compounds 4a-h on cell apoptosis was then evaluated by TUNEL assay ( Figure 5 ). Concentrations of 0.1 to 1.0 µM of compounds 4a-4f were used in the subsequent assays due to their antiproliferative effect without cytotoxic effect at these concentrations ( Figure 5A ). An increase in apoptosis was observed when
HUVECs were incubated with increasing concentrations of the tested compounds for 24 h, reaching statistical significance only for 4b-4d at the highest concentration tested (1.0 µM) in comparison to control. These findings indicate that besides the effects of these three compounds in HUVECs proliferation, they also induce apoptosis. Compounds 4a, 4e and 4f increased apoptosis in a dosedependent manner, but not with statistical significance ( Figure 5A ).
For compounds 4g and 4h, the concentrations selected for this and the following assays were 2.5 and 5.0 µM since they are the lowest concentrations of these compounds that have shown an antiproliferative effect without being cytotoxic to HUVECs ( Figure 3B and 4B). As shown in Figure   5B , 4g and 4h significantly increase apoptosis at 5.0 µM. Many studies report that Sorafenib induces apoptosis. 19 The findings in this study reveal that compounds 4g and 4h exhibited a higher effect than Sorafenib in apoptosis. expressed as mean ± SEM of at least three independent experiments. * p < 0.05 versus control.
Effect on HUVECs migration
Cell migration is an essential feature for endothelial cells in angiogenesis. Figure 6B ). These findings regarding Sorafenib effect in endothelial cell migration were corroborated by previous studies in the literature. 21 Nonetheless, incubation with compound 4h was more effective than Sorafenib, implying a better inhibitory role in this relevant angiogenic step. 
Effect on HUVECs tube formation
To elucidate the possible mechanisms of angiogenesis inhibition, tube formation ability of endothelial cells, which is also a critical step in the angiogenic process, was assessed in HUVECs.
As shown in Figure 7 , HUVECs plated on a Matrigel coated plate formed capillary-like structures in cells cultured in the absence of compounds (control). A significant decrease of these structures was observed whenever cells were incubated with compounds 4d-4f at concentrations of 0.5 to 5.0 µM, in a dose-dependent manner ( Figure 7A ). In the presence of compounds 4g, 4h or Sorafenib at concentrations of 2.5 and 5 µM, tube formation of HUVECs was significantly reduced ( Figure 7B ), except for 4g at 2.5 µM. This assay is a hallmark of angiogenesis evaluation in vitro. Interestingly, prevention of this process was also accomplished by every compound tested in the present study in a significant manner, implying thus, the important antiangiogenic role of these molecules. 
Effect on VEGFR-2 phosphorylation
The results presented herein were obtained in VEGF stimulated HUVECs cultures, implying that the compounds analyzed were able to exert their effects by interfering with VEGF signalling pathway.
To confirm this hypothesis, a Western blotting assay for total and phosphorylated (active) VEGF signalling pathway through the VEGFR-2 tyrosine kinase phosphorylation displays a crucial role in angiogenesis, namely, enhancing endothelial cell survival, proliferation and migration. 22 Many other signalling pathways are involved in angiogenesis, nevertheless, VEGF signalling, an angiogenic surrogate pathway, which is involved in the whole multistep process, from cell proliferation, migration, invasiveness capacity, anastomosis, ending up in the assembly of newly formed vascular structures. Therefore, we believe that inhibiting this pathway is an effective approach against angiogenesis. Our results showed that compounds 4 affect various steps of angiogenesis including endothelial cell proliferation, apoptosis, migration and capillary structure formation in a dose dependent manner.
In the present study we found that compounds 4 significantly block the tyrosine kinase phosphorylation of VEGFR-2, as observed by Western blotting in vitro, suggesting these compounds as potent VEGFR-2 inhibitors.
As far as our knowledge the S-linker in the meta position relative to the urea moiety constitutes a new substitution pattern that has not been disclosed in other known type II VEGFR-2 inhibitors.
This can thus be regarded as an interesting feature for the synthesis of new compounds with higher VEGFR-2 inhibitory activity and also for other scaffolds exploring the same VEGFR-2 binding conformation.
Although future studies, namely using animal models, are crucial, overall, our findings support the hypothesis that all these molecules are potent antiangiogenic agents.
Experimental Section
Synthesis
Melting points ( 
General synthesis procedure for compounds 2a-c:
In a flask with DMF (5 mL), compound 1, the aminothiophenol (1equiv.) and K 2 CO 3 (4equiv.) were heated at 140 ºC for 2h. After cooling water (5 mL) and ethyl acetate (5 mL) were added. The phases were separated and the aqueous phase was extracted with more ethyl acetate (2x5mL). The organic phase was dried (MgSO 4 ) and filtered. The solvent was evaporated under reduced pressure giving an oil which was submitted to column chromatography.
2-(Thieno[3,2-b]pyridin-7-ylthio)aniline (2a):
Compound 1 (150 mg, 0.880 mmol) and 2-aminothiophenol (110 mg) and the general procedure was followed. Column chromatography using 70% ether/petroleum ether gave compound 2a as an oil (180 mg, 80%). 
General procedure for the synthesis of 1,3-diarylureas 3-5: Compounds 2a-c and different
arylisocyanates (1equiv.) in 6 mL CH 2 Cl 2 : THF (1:1) were left stirring at room temperature for 12 h.
If a precipitate does not come out after this time, hexane (3-5 mL) was added to the mixture to precipitate the product. This was filtered under vacuum to give the corresponding 1,3-diarylureas. 1.2.6. 1-(4-Cyanophenyl)-3-[3-(thieno[3,2-b]pyridin-7-ylthio) 
1-Phenyl-3-[2-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (3a):
VEGFR-2 kinase inhibition assay
The compounds were assessed for VEGFR-2 inhibitory activity using the Z'-LYTE-Tyr1 Peptide assay kit (Invitrogen, Cat. PV3190) and according to the procedures recommended by the manufacturer. 12 Briefly, assays were performed in a total of 20 µL in 384-well plates using fluorescence resonance energy transfer technology. A Tyr1 substrate (coumarin-fluorescein doublelabeled peptide) at 1 µM was incubated for 1 h with 4 µg/mL VEGFR-2, 10 μM ATP, and inhibitors at room temperature in 50 mM Hepes/NaOH (pH 7.5), 10 mM MgCl 2 , 2 mM MnCl 2 , 2.5mM DTT, 0.10 mM orthovanadate, and 0.01% bovine serum albumin (BSA). Inhibitors were added to the wells with 4% DMSO added as solvent. The wells were incubated at 25 ºC for 1 h and 5 µL of development reagent was added to each well. After a second incubation of 1 h the stop reagent was added to each well. Using a Biotek FLX800 micro-plate the fluorescence was read at 445 nm and 520 nm (excitation 400 nm), and Gen5™ Software was used for data analysis. The validation assay was performed using Staurosporine that present an IC 50 value 6 nM that compares to the one reported in the literature. search rate of 0.06, 2.5 and 25 million energy evaluations. 23 Docked conformations were clustered using a tolerance of 2.0 Å RMSD. The entire virtual experiment was performed on a cluster of 64 AMD 2.0 GHz processor, using software MOLA. 24 The 3D compound-protein docking poses were analyzed manually using AutoDockTools, and Figure 1 was prepared using the software PyMOL. 
